Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego, dedicated to the discovery and development of innovative therapeutic products targeting significant unmet medical needs. Founded by a team with extensive experience in the industry, the company emphasizes areas such as immunology, inflammation, and oncology. Gossamer Bio's pipeline includes several promising candidates: Seralutinib, aimed at treating pulmonary arterial hypertension through the management of cellular overgrowth and vascular remodeling; GB004, designed for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; GB1275, targeting various oncology indications; and GB001, focused on moderate-to-severe eosinophilic asthma. The company's strategy involves leveraging in-licensing opportunities to enhance its asset portfolio and drive successful product development.